| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/15/2002 | US20020110814 Method and kit for the screening, the detection and/or the quantification of transcriptional factors |
| 08/15/2002 | US20020110609 Increasing retrievable fluid from a breast duct |
| 08/15/2002 | US20020110604 To inhibit the generation of free radicals and oxidative stress in animal; therapy |
| 08/15/2002 | US20020110600 For therapy of symptoms of colds and flu in humans |
| 08/15/2002 | US20020110598 Growth stimulant compositions |
| 08/15/2002 | US20020110594 Antibiotic/benzoyl peroxide dispenser |
| 08/15/2002 | US20020110586 Liposomal antineoplastic drugs and uses thereof |
| 08/15/2002 | US20020110569 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| 08/15/2002 | US20020110561 For use in therapy, sustained release of drugs |
| 08/15/2002 | US20020110560 Lowering elevated post-prandial blood glucose levels in mammals by increasing incretin half-life comprising administering inhibitor of Dipeptidyl Peptidase (DP IV) or enzymes having DP-IV-like activity |
| 08/15/2002 | US20020110559 Confering an immune response to a tumor cell in a mammal by administering antibody which binds to aspartyl (asparaginyl) beta hydroxylase (HAAH) |
| 08/15/2002 | US20020110551 Administering to the individual therapeutically effective amount of human acid alpha-glucosidase at regular interval for therapy of glycogen storage disease type II |
| 08/15/2002 | CA2441948A1 Glycine betaine and its use as anti-hemorrhagic agent |
| 08/15/2002 | CA2437727A1 Methods and compositions for modulating gluconeogenesis using pgc-1 |
| 08/15/2002 | CA2437717A1 G-protein coupled receptors |
| 08/15/2002 | CA2437573A1 Methods for diagnosing and treating heart disease |
| 08/15/2002 | CA2437571A1 Receptors and membrane-associated proteins |
| 08/15/2002 | CA2437570A1 Methods for diagnosing and treating heart disease |
| 08/15/2002 | CA2437497A1 Lipid-associated molecules |
| 08/15/2002 | CA2437434A1 Method for identifying compounds modulating reverse cholesterol transport |
| 08/15/2002 | CA2437423A1 Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals |
| 08/15/2002 | CA2437380A1 A treatment of oesophageal motility disorders and gastro-oesophageal reflux disease |
| 08/15/2002 | CA2437351A1 Composition and method for potentiating drugs |
| 08/15/2002 | CA2437214A1 Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
| 08/15/2002 | CA2437212A1 Methods and devices for tissue repair |
| 08/15/2002 | CA2437087A1 Methods for the administration of amifostine and related compounds |
| 08/15/2002 | CA2437085A1 Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists |
| 08/15/2002 | CA2437015A1 Combined use of factor vii polypeptides and factor ix polypeptides |
| 08/15/2002 | CA2436807A1 Combined use of factor vii polypeptides and factor viii polypeptides |
| 08/15/2002 | CA2436741A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents |
| 08/15/2002 | CA2436738A1 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
| 08/15/2002 | CA2436735A1 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof |
| 08/15/2002 | CA2436470A1 Intracellular signaling molecules |
| 08/15/2002 | CA2436465A1 Prediction of wound healing by urinary nitrate assay |
| 08/15/2002 | CA2435989A1 Pharmaceutical composition for the therapy of lower urinary tract symptoms |
| 08/15/2002 | CA2435835A1 Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
| 08/15/2002 | CA2435546A1 Rapid-onset medicament for the treatment of sexual dysfunction |
| 08/15/2002 | CA2435350A1 Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea |
| 08/15/2002 | CA2434944A1 Secreted proteins |
| 08/15/2002 | CA2405524A1 A personal condition management system |
| 08/14/2002 | EP1231211A1 Thiazolidinedione derivatives as antidiabetic agents |
| 08/14/2002 | EP1230933A1 Remedies for intractable wound |
| 08/14/2002 | EP1230925A1 Anti-hiv compositions |
| 08/14/2002 | EP1230921A1 Combination treatment for depression |
| 08/14/2002 | EP1230919A2 Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage |
| 08/14/2002 | EP1230918A2 An aqueous enteroclysis solution for the treatment of hepatic encephalopathy |
| 08/14/2002 | EP1230916A2 Aqueous medicament preparations for the production of propellant gas-free aerosols |
| 08/14/2002 | EP1230551A2 Methods to identify compounds that modulate neuronal activity |
| 08/14/2002 | EP1230379A2 Regulating endogenous inhibitor at atp synthase |
| 08/14/2002 | EP1230369A2 Polypeptide hormone phosphatonin |
| 08/14/2002 | EP1230368A2 Mammalian receptor proteins; related reagents and methods |
| 08/14/2002 | EP1230349A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 08/14/2002 | EP1230270A1 Antibodies binding a non naturally occurring enantiomer (l-biotin) and their use as targeting agents |
| 08/14/2002 | EP1230267A2 Membrane translocating peptide drug delivery system |
| 08/14/2002 | EP1230264A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |
| 08/14/2002 | EP1230230A1 Indeno-, naphtho-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments |
| 08/14/2002 | EP1230218A1 Positive modulators of nicotinic receptor agonists |
| 08/14/2002 | EP1230217A1 Positive modulators of nicotinic receptor agonists |
| 08/14/2002 | EP1230216A1 Positive modulators of nicotinic receptor agonists |
| 08/14/2002 | EP1229965A2 Placental human neurokinin b precursor |
| 08/14/2002 | EP1229954A1 Method of treating cardio pulmonary diseases with no group compounds |
| 08/14/2002 | EP1229942A1 Method and formula for tumor remission and suppression of cancer |
| 08/14/2002 | EP1229938A2 Potentiation of prodrug efficacy |
| 08/14/2002 | EP1229935A1 Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
| 08/14/2002 | EP1229934A2 Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| 08/14/2002 | EP1229922A2 Aplidine treatment of cancers |
| 08/14/2002 | EP1229920A1 Therapy with 2-5a and interferon |
| 08/14/2002 | EP1229918A2 Pharmaceutical composition comprising a combination of metformin and glibenclamide |
| 08/14/2002 | EP1229916A2 Combination chemotherapy |
| 08/14/2002 | EP1229910A1 Integrin receptor antagonists |
| 08/14/2002 | EP1229908A1 USE OF NSAIDs FOR THE TREATMENT OF PANCREATIC CANCER |
| 08/14/2002 | EP1229907A1 Prevention of plaque rupture by acat inhibitors |
| 08/14/2002 | EP1229906A2 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders |
| 08/14/2002 | EP1229903A1 A method for chemoprevention of prostate cancer |
| 08/14/2002 | EP1229897A2 Personal care articles comprising cationic polymer coacervate compositions |
| 08/14/2002 | EP1229895A1 Slimming composition containing a substance inducing il-6 production |
| 08/14/2002 | EP1187591A4 Ibd-associated microbial antigens and methods of using same |
| 08/14/2002 | EP0977582B1 Pharmaceutical combined preparations containing erythropoietin and iron preparations |
| 08/14/2002 | EP0800399B1 Combined therapeutical treatment of hyperproliferative diseases |
| 08/14/2002 | EP0794772B1 Medicaments for enhancing outflow of aqueous humor in treatment of glaucoma |
| 08/14/2002 | DE10103565A1 Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus Compositions comprising a ruthenium (III) complex and a heterocycle |
| 08/14/2002 | DE10103506A1 Pharmazeutische Zusammensetzung zur Behandlung von Multiple Sklerose A pharmaceutical composition for the treatment of Multiple Sclerosis |
| 08/14/2002 | CN1364171A Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 08/14/2002 | CN1364167A Endogenous constitutively activated G protein-coupled orphan receptors |
| 08/14/2002 | CN1364155A N-Cyanomethyl amides as protease inhibitors |
| 08/14/2002 | CN1364153A Substituted phenoxyacetic acids |
| 08/14/2002 | CN1364093A Improvement of T cell mediated immunity |
| 08/14/2002 | CN1364092A Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
| 08/14/2002 | CN1364087A Methods of treatment and drug screening methods |
| 08/14/2002 | CN1364086A Use of interleukin-18 inhibitors to inhibitor tumor metastasis |
| 08/14/2002 | CN1364085A Use of phyllanthus for treating chronically inflammatory and fibrotic processes |
| 08/14/2002 | CN1364084A Method of inducing cancer cell death and tumor regression |
| 08/14/2002 | CN1364079A Transnasal anticonvulsive compositions and modulated process |
| 08/14/2002 | CN1364073A Skin care composition for mediating cell to cell communication |
| 08/13/2002 | US6433451 Method and electric motor with rotational stator |
| 08/13/2002 | US6433182 Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| 08/13/2002 | US6433171 Dipeptide derivatives |
| 08/13/2002 | US6433138 Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids |
| 08/13/2002 | US6433040 Administering nonaqueous suspension in liquid fluorochemical with plurality of perforated microstructures filled with bioactive agent dispersed therin to nose or lungs; drug delivery |
| 08/13/2002 | US6433027 Medicament compositions based on tiotropium bromide and formoterol fumarate |